Dimensional Fund Advisors LP Sells 266,901 Shares of OPKO Health, Inc. (NASDAQ:OPK)

Dimensional Fund Advisors LP decreased its holdings in shares of OPKO Health, Inc. (NASDAQ:OPK) by 9.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,654,535 shares of the biotechnology company’s stock after selling 266,901 shares during the quarter. Dimensional Fund Advisors LP’s holdings in OPKO Health were worth $3,319,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of OPK. CIBC Asset Management Inc raised its position in OPKO Health by 79.1% during the second quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 8,978 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of OPKO Health during the first quarter valued at about $26,000. Moseley Investment Management Inc. acquired a new stake in OPKO Health in the first quarter valued at approximately $41,000. Headlands Technologies LLC bought a new stake in OPKO Health during the 1st quarter valued at $47,000. Finally, American Century Companies Inc. acquired a new stake in shares of OPKO Health in the 2nd quarter worth about $112,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

Insider Transactions at OPKO Health

In other news, major shareholder Opko Health, Inc. sold 50,000 shares of the company’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $34.49, for a total transaction of $1,724,500.00. Following the transaction, the insider now owns 2,646,972 shares in the company, valued at $91,294,064.28. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last ninety days, insiders have sold 636,444 shares of company stock worth $21,125,127. Insiders own 47.26% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on OPK. Piper Sandler reaffirmed an “overweight” rating and set a $3.00 target price on shares of OPKO Health in a research report on Tuesday, September 17th. StockNews.com raised OPKO Health to a “sell” rating in a research note on Saturday, July 27th. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a research note on Thursday, September 26th. Finally, Barrington Research restated an “outperform” rating and issued a $2.25 price objective on shares of OPKO Health in a report on Friday, September 20th.

OPKO Health Stock Down 2.0 %

Shares of OPK stock opened at $1.47 on Friday. OPKO Health, Inc. has a 12 month low of $0.85 and a 12 month high of $1.75. The stock has a market cap of $1.02 billion, a P/E ratio of -4.20 and a beta of 1.63. The company has a 50 day simple moving average of $1.54 and a two-hundred day simple moving average of $1.39. The company has a current ratio of 1.63, a quick ratio of 1.36 and a debt-to-equity ratio of 0.13.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.08. The company had revenue of $182.20 million during the quarter, compared to analyst estimates of $184.70 million. OPKO Health had a negative return on equity of 17.67% and a negative net margin of 33.79%. The firm’s revenue was down 31.3% on a year-over-year basis. During the same period in the prior year, the company earned ($0.03) earnings per share. On average, research analysts expect that OPKO Health, Inc. will post -0.29 earnings per share for the current year.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.